Core Insights - The article discusses the ongoing efforts in China to support innovative drugs while addressing the challenges of pricing and payment systems, particularly focusing on the introduction of the "Category C" drug list and its implications for commercial health insurance [1][2]. Group 1: Category C Drug List - The Category C drug list is set to be explored and formed by 2025, with the first version expected to be released within the year, aligning with adjustments to the national basic medical insurance drug list [1][2]. - Experts indicate that the timing for the implementation of the Category C list is still uncertain, and it will focus on drugs that are clinically needed, innovative, and priced higher than those covered by basic insurance [3][6]. - The Category C list aims to provide a new payment pathway for innovative drugs that exceed the current insurance payment limits but meet clinical needs [4][5]. Group 2: Commercial Health Insurance Drug List - The commercial health insurance drug list is being accelerated by the China Insurance Industry Association, aiming to create a comprehensive multi-tiered drug directory that includes drugs approved by domestic and international regulatory bodies [7][8]. - The initial draft of the A-series list has been circulated for industry feedback, focusing on specific drugs and their therapeutic indications, with a total of 2,619 drugs being considered [7]. - The commercial health insurance model differs from the Category C list as it is driven by market demand and user willingness to pay, allowing for a more flexible and diverse drug directory [8][9]. Group 3: Economic Evaluation and Pricing - The use of pharmacoeconomic evaluations is suggested to enhance the pricing and payment processes for innovative drugs, providing a scientific basis for negotiations between pharmaceutical companies and insurance departments [5][6]. - The current payment structure shows that in 2024, the market size for innovative drugs is projected to reach 162 billion yuan, with insurance covering only 44% of costs, indicating a significant reliance on out-of-pocket expenses [7].